Clinical trial
A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care…
NCT01140347 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT01140347 |
|---|---|
| Title | A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib |
| Official title | A Multicenter, Randomized, Double-Blind, Phase 3 Study of Ramucirumab (IMC-1121B) Drug Product and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma Following First-Line Therapy With Sorafenib (REACH) |
| Acronym | REACH |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hepatocellular Carcinoma |
| Intervention type | Biological, Other |
| Interventions | Placebo, Ramucirumab DP (IMC-1121B), BSC |
| Enrollment | 565 |
| Start date | Oct 1, 2010 |
| Primary completion | Mar 1, 2014 |
| Completion | Mar 1, 2015 |
| First posted | Jun 9, 2010 |
| Last update posted | Dec 28, 2015 |
| Countries | Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Czechia, Finland, France, Germany, Hong Kong, Hungary and 15 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: